EW
Therapeutic Areas
GSK Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bepirovirsen | Chronic Hepatitis B | Phase III |
| Jemperli (dostarlimab) + Chemo | 1L Endometrial Cancer | Phase III |
| Jemperli (dostarlimab) | 1L dMMR/MSI-H Colorectal Cancer | Phase III |
| Blenrep (belantamab mafodotin) | Relapsed/Refractory Multiple Myeloma | Phase III |
| Depemokimab (GSK3511294) | Severe Asthma | Phase III |
| MenABCWY Vaccine | Meningococcal Disease | Phase III |
| Cabotegravir Long-Acting (CAB-LA) | HIV PrEP | Approved |
| RSV Maternal Vaccine | RSV in Infants | Approved |
Leadership Team at GSK
TW
Tony Wood
Chief Scientific Officer
JB
Julie Brown
Chief Financial Officer & Chief Operating Officer
DW
Deborah Waterhouse
CEO, ViiV Healthcare
SL
Sabine Luik
Senior Vice President, Medicine Development & Supply
HA
Hesham Ahmed Abdullah
Senior Vice President, Global Commercial Strategy
KK
Kaivan Khavandi
Senior Vice President, Respiratory & Immunology R&D